I am trained as both an Infectious Disease specialist and as an expert in innate defense against bacterial infection, with a focus on Gram-negative organisms. As an Infectious Disease specialist, I am particularly interested in treatment approaches to multidrug-resistant Gram-negative infections. As a researcher, I study the innate defenses against these types of infections. In one project, I study the Bactericidal/Permeability-Increasing protein (BPI) - an endogenous antibiotic found in neutrophils and available in recombinant form. BPI has potent activity against Gram-negative bacteria, including multidrug-resistant clinical isolates I collect.
I have also studied emerging infections, such as chikungunya, Zika and seasonal influenza. I was engaged in two NIH-sponsored clinical trials for the treatment of seasonal influenza with immune plasma and triple therapy (ribivirin, oseltamivir and amantadine). I was the Principal Investigator for UF site of the NIH-sponsored Adaptive COVID-19 Treatment Trials (ACTT), which identified remdesivir and baricitinib as important agents for the treatment of COVID patients. Most recently, I am the Principal Investigator for the UF site of the STOMP monkeypox clinical trial, and for the Accelerating COVID-19 Therapeutic Interventions and Vaccines clinical trials (ACTIV4a and ACTIV4d).
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
Investigator
Nicole M Iovine
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
My publications
Filter publications
47 publications
2021
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
The New England journal of medicine
•
2021
Disseminated genitourinary histoplasmosis in a patient with AIDS with negative urine antigen testing.
BMJ case reports
•
2021
Dissemination mechanisms of NDM genes in hospitalized patients.
JAC-antimicrobial resistance
•
2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Respiratory medicine
•
2020
Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae.